Register for our free email digests:
Latest From Repligen Corp.
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Allergan rebounded from the derailed Pfizer acquisition by signing a $3 billion partnership with Heptares to develop small-molecule muscarinic receptor agonists in CNS diseases; there was a huge consolidation in cardiovascular devices through Abbott's $25 billion purchase of St. Jude Medical. Biopharma funding totaled $1.1 billion, while device fundraising reached $248 million.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014-January 2015.
Repligen will not remain a part of Pfizer's "underappreciated" research and development pipeline, since the big pharma has ended its partnership with the Waltham, Massachusetts-based biotechnology company.
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- KemPharm Inc.
- Senior Management
Travis C Mickle, PhD, Pres. & CEO
R. LaDuane Clifton, CFO
Christopher Lauderback, PhD, VP, Commercial Ops.
Sven Guenther, PhD, VP, Res.
Gordon "Rusty" K Johnson, CBO
Rene A Braeckman, PhD, VP, Clinical Dev.
- Contact Info
Phone: (319) 665-2575
2656 Crosspark Rd.
Coralville, IA 52241
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.